PMPRB reaches agreement with Baxalta Canada on reporting requirements for leukemia drug
Friday, November 04, 2016
Canada's drug price watchdog reaches agreement with drug-maker on reporting requirements for leukemia drug. Hearing panel issued order on Oct 28, requiring Baxalta Canada to provide PMPRB with requirements for leukemia drug.
Issued order to Baxalta to provide PMPRB with pricing,sales info required by section 80 of Patent Act,sections 3 and 4 of Patented Medicines Regulations.
Order relates to medicine Oncaspar, which is used in treatment of patients with acute lymphoblastic leukemia. Baxalta agreed to provide information sought by PMPRB for period commencing July 1, 2015, when Baxalta began selling Oncaspar in Canada.
Hearing panel's order resolved matter with Baxalta and, as such, no hearing will be held in November 2016.
Source : reuters.com
